Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmace
ARS Pharmaceuticals, Inc. Is Being Looked Into For Securities Law Violations And The Schall Law Firm Invites Investors To Take Part
11:00am, Wednesday, 11'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmace
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
04:05pm, Tuesday, 10'th Sep 2024
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves
If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc's Possible Securities Fraud And Shareholders Are Invited To Contribute
11:00am, Saturday, 07'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why
01:00pm, Friday, 06'th Sep 2024
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
04:05am, Friday, 06'th Sep 2024
ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need, pot
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
ARS Pharmaceuticals Inc. May Have Defrauded The Public And The Schall Law Firm Wants Impacted Investors To Reach Out About An Inquiry
11:00am, Wednesday, 04'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
ARS Pharmaceuticals Inc. May Have Violated Securities Laws And The Schall Law Firm Seeks Investor Participation In An Inquiry
11:00am, Monday, 02'nd Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceu
ARS Pharmaceuticals Inc. Might Have Committed Securities Law Violations And The Schall Law Firm Wants Investors To Partake In An Inquiry
11:00am, Saturday, 31'st Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
